Why Do Japans Advanced Medical Treatments Never Get Ahead?
スポンサーリンク
概要
- 論文の詳細を見る
Islet cell transplantation is a minimally invasive procedure which effectively controls blood glucose level for diabetic patients but is considered as experimental. After islet transplantation, type 1 diabetic patients could become insulin free with stable glycemic control. But for long term effects, only stable glycemic control was maintained and not insulin free status. In 2004 Kyoto University performed the first Japanese islet cell transplant using non-heart beating donor. Of note, due to the lack of cadaveric donors in Japan, the same group performed the worlds first successful case of living donor islet transplantation in 2005. Both patients achieved transit insulin-independence; however excellent glycemic control was able to be maintained for a prolonged period. Even though the series of islet transplants at Kyoto University showed promising results, the leading scientist did not continue his research in Japan. This was because it is extremely difficult to implement newly developed treatment as a standard therapy in Japan.
著者
-
Kami Masahiro
Division Of Exploratory Research Institute Of Medical Science University Of Tokyo
-
TANAKA Yuji
Division of Exploratory Research,the Institute of Medical Science, the University of Tokyo
-
Hatanaka Nobuyo
Division of Social Communication System for Advanced Clinical Research, the Institute of Medical Sci
-
Matsumoto Shinichi
Division of Social Communication System for Advanced Clinical Research, the Institute of Medical Sci
関連論文
- Why Do Japans Advanced Medical Treatments Never Get Ahead?
- Phase II study of tacrolimus and methotrexate for prophylaxis of acute graft-versus-host disease after HLA-A, B, and DRB1 genotypically mismatched unrelated bone marrow transplantation among Japanese patients
- Different Kinetics of WT1 and PML-RARα Gene Expression Levels during Remission Induction Therapy with All-trans Retinoic Acid Alone in Acute Promyelocytic Leukemia
- Current status of development of anticancer agents in Japan
- Safety and usefulness of emergency maternal transport using helicopter
- Regional differences exist in allogeneic stem cell transplantation rates for acute leukemia
- Postmortem examination of the kidney in allogeneic hematopoietic stem cell transplantation recipients : possible involvement of graft-versus-host disease
- Graft-versus-Myeloma Effects in Reduced-Intensity Cord Blood Transplantation
- A study of cancer information for cancer patients on the internet
- Prevalence of Anemia among Healthy Women in 2 Metropolitan Areas of Japan
- Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies
- Increase Incidence of Lymphoid Malignancies in Patients Receiving Statins and Their Clinical Characteristics : A Case-Control Study Involving 1100 Patients
- A Prospective Surveillance of Nosocomial Respiratory Syncytial Virus Infection in a Hematology Ward: A Single-Center Experience in Japan
- Early Diagnosis of Central Nervous System Aspergillosis with Combination Use of Cerebral Diffusion-weighted Echo-planar Magnetic Resonance Image and Polymerase Chain Reaction of Cerebrospinal Fluid
- Peripheral blood stem cell versus bone marrow transplantation from HLA-identical sibling donors in patients with leukemia : a propensity score-based comparison from the Japan Society for Hematopoietic Stem Cell Transplantation registry
- Fulminant Septicemic Syndrome of Bacillus cereus in a Leukemic Patient
- Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8^+ T cells in patients with myeloid malignancies
- Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway
- Preventative Effect of a Flavonoid, Enzymatically Modified Isoquercitrin on Ocular Symptoms of Japanese Cedar Pollinosis
- Mylotarg Is Not a "Magic Bullet"
- Low-Dose Cyclosporin A with Short-Term Methotrexate for Graft-versus-Host Disease Prophylaxis in Allogeneic Bone Marrow Transplantation from Human Leukocyte Antigen-Identical Siblings : A Prospective Phase II Study in Japanese Patients
- Wilms Tumor Gene WT1 Peptide-Based Immunotherapy Induced a Minimal Response in a Patient with Advanced Therapy-Resistant Multiple Myeloma
- WT1_, a Ninemer Peptide Derived from Wilms' Tumor Gene Product, Is a Candidate Peptide for the Vaccination of HLA-A^*0201-Positive Patients with Hematopoietic Malignancies
- Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro
- WT1 (Wilms' Tumor 1) Peptide Immunotherapy for Renal Cell Carcinoma
- Minimal influence of tocilizumab on IFN-γ synthesis by tuberculosis antigens
- Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation
- Radiofrequency Catheter Ablation with the Use of a Noncontact Mapping System for Ventricular Tachycardia Originating from the Aortic Sinus Cusp : A Case Report
- A case of Mikulicz's disease with Th2-biased cytokine profile : possible feature discriminable from Sjogren's syndrome
- Structural problems of medical news reports in newspapers : a verification of news reports on an incident of mass nosocomial Serratia infection
- Feasibility and Obstacles in Home Chemotherapy for Malignant Lymphoma
- AL amyloidosis with IgD-lambda monoclonal gammopathy and lambda-type Bence-Jones protein : successful treatment by autologous stem cell transplantation
- Severe polyuria after the resection of adrenal pheochromocytoma
- Identification of a WT1 protein-derived peptide, WT1_, : as a HLA-A^*0206-restricted, WT1-specific CTL epitope
- A WT1 protein-derived, naturally processed 16-mer peptide, WT1_, is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4^+ T cells
- Why Do Japan's Advanced Medical Treatments Never Get Ahead?
- Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab
- Development of a novel scale to assess the quality of life in type 1 diabetic patients for beta cell replacement therapy